Work

A phase II study of dihydroxyanthracenedione (DHAD, Mitoxantrone, NSC 301739) in advanced malignant melanoma

Year: 1986

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/bf00172017

Authors: James C. Arseneau, David A. Schoenfeld, Ernest C. Borden

Institutions: University of Rochester Medicine, University of Rochester, Dana-Farber Cancer Institute, University of Wisconsin Carbone Cancer Center

Language: English

Topic: Cutaneous Melanoma Detection and Management

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute

Awards: Southwest Oncology Group, EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES, ECOG Statistical Office

OpenAlex ID: W2003215063

FWCI: 0.305

Cites: 5

Cited by: 10

Related to: 10